Effect of resveratrol and rosuvastatin on experimental diabetic nephropathy in rats

Biomedicine and Pharmacotherapy

Volumn 82, Issue , 2016, Pages 685-692

  Hussein, Mohamed M A ^a   Mahfouz, Mohamed K ^b  

^a Zagazig University   (Egypt)

^b Benha University   (Egypt)

Author keywords

Diabetic nephropathy; FoxO1; Resveratrol; Rosuvastatin; Sirt1

Indexed keywords

CATALASE; CREATININE; FIBRONECTIN; GLUCOSE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HEMOGLOBIN A1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; MESSENGER RNA; RESVERATROL; ROSUVASTATIN; SIRTUIN 1; SUPEROXIDE DISMUTASE; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA1; ANTIOXIDANT; FOXO1 PROTEIN, RAT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; NERVE PROTEIN; STILBENE DERIVATIVE;

ALBINO RAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES CONTROL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; ENZYME ACTIVITY; EXPERIMENTAL DIABETIC NEPHROPATHY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; KIDNEY DYSFUNCTION; KIDNEY INJURY; KIDNEY MASS; KIDNEY PARENCHYMA; MALE; NONHUMAN; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; ANIMAL; BLOOD; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KIDNEY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FIBRONECTINS; GENE EXPRESSION REGULATION; HEMOGLOBIN A, GLYCOSYLATED; KIDNEY; MALE; NERVE TISSUE PROTEINS; NF-KAPPA B; OXIDATIVE STRESS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; ROSUVASTATIN CALCIUM; SIRTUIN 1; STILBENES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84979518770     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.06.004     Document Type: Article

References (56)

1. [1] Forbes, J.M., Cooper, M.E., Oldfield, M.D., Thomas, M.C., Role of advanced glycation end products in diabetic nephropathy. J. Am. Soc. Nephrol. 14:8 Suppl. 3 (2003), S254–8.
2. [2] Yamagishi, S., Matsui, T., Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid. Med. Cell. Longevity 3:2 (2010), 101–108.
3. [3] Ha, H., Hwang, I.A., Park, J.H., Lee, H.B., Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res. Clin. Pract. 82:Suppl. 1 (2008), 42–45.
4. [4] Ha, H., Lee, H.B., Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int. 77:Supplement (2000), 19–25.
5. [5] Kitada, M., Kume, S., Imaizumi, N., Koya, D., Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 60:2 (2011), 634–643.
6. [6] Hussein, M.M., Ahmed, M.M., The Th1/Th2 paradigm in lambda cyhalothrin-induced spleen toxicity: the role of thymoquinone. Environ. Toxicol. Pharmacol. 41 (2016), 14–21.
7. [7] Ho, K.K., Myatt, S.S., Lam, E.W., Many forks in the path: cycling with FoxO. Oncogene 27:16 (2008), 2300–2311.
8. [8] Kato, M., Yuan, H., Xu, Z.G., Lanting, L., Li, S.L., Wang, M., Hu, M.C., Reddy, M.A., Natarajan, R., Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J. Am. Soc. Nephrol. 17:12 (2006), 3325–3335.
9. [9] Su, D., Coudriet, G.M., Hyun Kim, D., Lu, Y., Perdomo, G., Qu, S., Slusher, S., Tse, H.M., Piganelli, J., Giannoukakis, N., Zhang, J., Dong, H.H., FoxO1 links insulin resistance to proinflammatory cytokine IL-1beta production in macrophages. Diabetes 58:11 (2009), 2624–2633.
10. [10] Kitada, M., Koya, D., Renal protective effects of resveratrol. Oxid. Med. Cell. Longevity, 2013, 2013, 568093.
11. [11] Griscavage, J.M., Wilk, S., Ignarro, L.J., Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-kappa B. Proc. Natl. Acad. Sci. U.S.A. 93:8 (1996), 3308–3312.
12. [12] Yamagishi, S., Maeda, S., Matsui, T., Ueda, S., Fukami, K., Okuda, S., Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim. Biophys. Acta 1820:5 (2012), 663–671.
13. [13] Adetola, F.O., Adetola, O.I., Statin therapy in the management of diabetes mellitus; how relevant?. Am. Med. J. 4:1 (2013), 36–42.
14. [14] Chang, C.C., Chang, C.Y., Wu, Y.T., Huang, J.P., Yen, T.H., Hung, L.M., Resveratrol retards progression of diabetic nephropathy through modulations of oxidative stress, proinflammatory cytokines, and AMP-activated protein kinase. J. Biomed. Sci., 18(1), 2011, 47.
15. [15] Gedik, E., Girgin, S., Ozturk, H., Obay, B.D., Buyukbayram, H., Resveratrol attenuates oxidative stress and histological alterations induced by liver ischemia/reperfusion in rats. World J. Gastroenterol. 14:46 (2008), 7101–7106.
16. [16] Rosario, R.F., Prabhakar, S., Lipids and diabetic nephropathy. Curr. Diab. Rep. 6:6 (2006), 455–462.
17. [17] Haslinger-Loffler, B., Multiple effects of HMG-CoA reductase inhibitors (statins) besides their lipid-lowering function. Kidney Int. 74:5 (2008), 553–555.
18. [18] Mima, A., Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets. J. Diab. Res., 2013, 1–8.
19. [19] Liu, L., Gao, C., Chen, G., Li, X., Li, J., Wan, Q., Xu, Y., Notch signaling molecules activate TGF- beta in rat mesangial cells under high glucose conditions. J Diabetes Res, 2013, 2013, 979702.
20. [20] Loeffler, I., Wolf, G., Transforming growth factor-beta and the progression of renal disease. Nephrol. Dial. Transplant. 29:Suppl. 1 (2014), i37–i45.
21. [21] Ismail, T.A., Soliman, M.M., Ismail, S.A., Adiponectin regulation in type 2 diabetic rats: effects of insulin, metformin and dexamethasone. Am. J. Pharmacol. Toxicol. 8:4 (2013), 197–208.
22. [22] Palsamy, P., Sivakumar, S., Subramanian, S., Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats. Chem. Biol. Interact. 186:2 (2010), 200–210.
23. [23] Sironi, L., Gianazza, E., Gelosa, P., Guerrini, U., Nobili, E., Gianella, A., Cremonesi, B., Paoletti, R., Tremoli, E., Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects. Arterioscler. Thromb. Vasc. Biol. 25:3 (2005), 598–603.
24. [24] Heinegard, D., Tiderstrom, G., Determination of serum creatinine by a direct colorimetric method. Clin. chim. acta; Int. J. Clin. Chem. 43:3 (1973), 305–310.
25. [25] Trinder, P., Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J. Clin. Pathol. 22:2 (1969), 158–161.
26. [26] Orsonneau, J.L., Douet, P., Massoubre, C., Lustenberger, P., Bernard, S., An improved pyrogallol red-molybdate method for determining total urinary protein. Clin. Chem. 35:11 (1989), 2233–2236.
27. [27] McGowan, T.A., Stimulation of urinary TGF- and isoprostanes in response to hyperglycemia in humans. Clin. J. Am. Soc. Nephrol. 1:2 (2006), 263–268.
28. [28] Hussein, M.M., Ali, H.A., Ahmed, M.M., Ameliorative effects of phycocyanin against gibberellic acid induced hepatotoxicity. Pestic. Biochem. Physiol. 119 (2015), 28–32.
29. [29] Nair, V., Turner, G.A., The thiobarbituric acid test for lipid peroxidation: structure of the adduct with malondialdehyde. Lipids 19 (1984), 84–85.
30. [30] Beutler, E., Effect of flavin compounds on glutathione reductase activity: in vivo and in vitro studies. J. Clin. Invest. 48:10 (1969), 1957–1966.
31. [31] Sinha, A.K., Colorimetric assay of catalase. Anal. Biochem. 47:2 (1972), 389–394.
32. [32] Misra, H.P., Fridovich, I., The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J. Biol. Chem. 247:10 (1972), 3170–3175.
33. [33] Paglia, D.E., Valentine, W.N., Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 70:1 (1967), 158–169.
34. [34] Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta C(T)) method. Methods 25:4 (2001), 402–408.
35. [35] Wilson, I., Gamble, M., The hematoxylins and eosins. Bancrof, J.D., Gamble, M., (eds.) Theory and Practice of Histological Techniques, 2008, Elsevier Health Sciences, London, UK, 125–138.
36. [36] Palsamy, P., Subramanian, S., Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic beta-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats. J. Cell. Physiol. 224:2 (2010), 423–432.
37. [37] Su, H.C., Hung, L.M., Chen, J.K., Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab. 290:6 (2006), E1339–E1346.
38. [38] Palsamy, P., Subramanian, S., Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats. Chem. Biol. Interact. 179:2–3 (2009), 356–362.
39. [39] Beckman, J.S., Koppenol, W.H., Nitric oxide superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. 271:5 Pt. 1 (1996), 1424–1437.
40. [40] Rice-Evans, C.A., Miller, N.J., Bolwell, P.G., Bramley, P.M., Pridham, J.B., The relative antioxidant activities of plant-derived polyphenolic flavonoids. Free Radic. Res. 22:4 (1995), 375–383.
41. [41] Chen, K.H., Cheng, M.L., Jing, Y.H., Chiu, D.T., Shiao, M.S., Chen, J.K., Resveratrol ameliorates metabolic disorders and muscle wasting in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab. 301:5 (2011), 853–863.
42. [42] Ku, C.R., Lee, H.J., Kim, S.K., Lee, E.Y., Lee, M.K., Lee, E.J., Resveratrol prevents streptozotocin-induced diabetes by inhibiting the apoptosis of pancreatic beta-cell and the cleavage of poly (ADP-ribose) polymerase. Endocr. J. 59:2 (2012), 103–109.
43. [43] Chong, P.H., Seeger, J.D., Franklin, C., Clinically relevant differences between the statins: implications for therapeutic selection. Am. J. Med. 111:5 (2001), 390–400.
44. [44] Ross, R., Atherosclerosis–an inflammatory disease. N. Engl. J. Med. 340:2 (1999), 115–126.
45. [45] Yada, T., Nakata, M., Shiraishi, T., Kakei, M., Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br. J. Pharmacol. 126:5 (1999), 1205–1213.
46. [46] Okada, K., Maeda, N., Kikuchi, K., Tatsukawa, M., Sawayama, Y., Hayashi, J., Pravastatin improves insulin resistance in dyslipidemic patients. J. Atheroscler. Thromb. 12:6 (2005), 322–329.
47. [47] Guclu, F., Ozmen, B., Hekimsoy, Z., Kirmaz, C., Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed. pharmacother. 58:10 (2004), 614–618.
48. [48] Tarhzaoui, K., Valensi, P., Leger, G., Cohen-Boulakia, F., Lestrade, R., Behar, A., Rosuvastatin positively changes nerve electrophysiology in diabetic rats. Diabetes Metab. Res. Rev. 25:3 (2009), 272–278.
49. [49] Giunti, S., Calkin, A.C., Forbes, J.M., Allen, T.J., Thomas, M.C., Cooper, M.E., Jandeleit-Dahm, K.A., The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. Am. J. Physiol. Renal Physiol. 299:3 (2010), 528–535.
50. [50] Anderson, T.J., Meredith, I.T., Yeung, A.C., Frei, B., Selwyn, A.P., Ganz, P., The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med. 332:8 (1995), 488–493.
51. [51] Forbes, J.M., Coughlan, M.T., Cooper, M.E., Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57:6 (2008), 1446–1454.
52. [52] Li, J., Qu, X., Ricardo, S.D., Bertram, J.F., Nikolic-Paterson, D.J., Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3. Am. J. Pathol. 177:3 (2010), 1065–1071.
53. [53] Chen, K.H., Hung, C.C., Hsu, H.H., Jing, Y.H., Yang, C.W., Chen, J.K., Resveratrol ameliorates early diabetic nephropathy associated with suppression of augmented TGF-beta/smad and ERK1/2 signaling in streptozotocin-induced diabetic rats. Chem. Biol. Interact. 190:1 (2011), 45–53.
54. [54] Jing, Y.H., Chen, K.H., Yang, S.H., Kuo, P.C., Chen, J.K., Resveratrol ameliorates vasculopathy in STZ-induced diabetic rats: role of AGE-RAGE signalling. Diabetes Metab. Res. Rev. 26:3 (2010), 212–222.
55. [55] Wu, L., Zhang, Y., Ma, X., Zhang, N., Qin, G., The effect of resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats. Mol. Biol. Rep. 39:9 (2012), 9085–9093.
56. [56] Price, N.L., Gomes, A.P., Ling, A.J., Duarte, F.V., Martin-Montalvo, A., North, B.J., Agarwal, B., Ye, L., Ramadori, G., Teodoro, J.S., Hubbard, B.P., Varela, A.T., Davis, J.G., Varamini, B., Hafner, A., Moaddel, R., Rolo, A.P., Coppari, R., Palmeira, C.M., de Cabo, R., Baur, J.A., Sinclair, D.A., SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 15:5 (2012), 675–690.